International Journal of Clinical Oncology · 2017 · 38 citations · 14 references
MedicineOncologyPharmacologyChemotherapyOncology PharmacotherapySurvival AnalysisCancer Survival AnalysisColorectal CancerMetastatic Cancer ManagementSurvival OutcomesToxicity GradingToxicity ManagementClinical Trial Efficacy EndpointsColorectal Cancer PrognosisEligibility Criteria DevelopmentMedical Records ReviewPrognostic Factors AnalysisSurvival Analysis In TrialsSurvival Endpoints Validation
BACKGROUND: The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients. We assessed the feasibility and effectiveness of trifluridine/tipiracil in daily clinical practice in The Netherlands. METHODS: Medical records of patients from 17 centers treated in the trifluridine/tipiracil compassionate use program were reviewed and checked for RECOURSE eligibility criteria. Baseline characteristics, safety, and survival times were compared, and prespecified baseline characteristics were tested in multivariate analyses for prognostic significance on overall survival (OS). RESULTS: A total of 136 patients with a median age of 62 years were analyzed. Forty-three patients (32%) did not meet the RECOURSE eligibility criteria for not having received all prior standard treatments (n = 35, 26%) and/or ECOG performance status (PS) 2 (n = 12, 9%). The most common grade ≥3 toxicities were neutropenia (n = 44, 32%), leukopenia (n = 8, 6%), anemia (n = 7, 5%), and fatigue (n = 7, 5%). Median progression-free survival (PFS) and median OS were 2.1 (95% CI, 1.8-2.3) and 5.4 months (95% CI, 4.0-6.9), respectively. Patients with ECOG PS 2 had a worse median OS (3.2 months) compared to patients with ECOG PS 0-1 (5.9 months). ECOG PS, KRAS-mutation status, white blood cell count, serum lactate dehydrogenase, and alkaline phosphatase were prognostic factors for OS. CONCLUSIONS: Our data show that treatment with trifluridine/tipiracil in daily clinical practice is feasible and safe. Differences in patient characteristics between our population and the RECOURSE study population should be taken into account in the interpretation of survival data. Our results argue against the use of trifluridine/tipiracil in patients with ECOG PS 2. FUNDING: Johannes J.M. Kwakman received an unrestricted research grant from Servier.
14
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer, Eric Van Cutsem, Alfredo Falcone et al. · New England Journal of Medicine · 2015 · 1.4K citations · Full text
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
Holly G. Prigerson, Yuhua Bao, Manish A. Shah et al. · JAMA Oncology · 2015 · 651 citations · Full text
Medicine, Oncology, Chemotherapy +15
C.-H. Köhne, David Cunningham, Francesco Di Costanzo et al. · Annals of Oncology · 2002 · 458 citations · Full text
Medicine, Biostatistics, Oncology +12
Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines
Daniel G. Haller, Jim Cassidy, Stephen Clarke et al. · Journal of Clinical Oncology · 2008 · 253 citations · Full text
Medicine, Oncology, Pharmacology +16